COX-2 inhibitors.

摘要: Cyclooxygenase-2 (COX-2) inhibitors constitute a new group of non-steroidal anti-inflammatory drugs (NSAIDs) which, at recommended doses, block prostaglandin production by cyclooxygenase-2, but not cyclooxygenase-1. Two COX-2 are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, once daily. Both act rapidly providing pain relief their analgesic effect osteoarthritis rheumatoid arthritis equivalent to standard doses non-selective NSAIDs. Celecoxib rofecoxib show significantly lower incidences gastrotoxicity (as measured endoscopic studies gastrointestinal ulcers bleeds) than There Level 2 evidence that inhibitors: reduce classic models--third-molar extraction, dysmenorrhoea after orthopaedic surgery; disability the hip knee; arthritis. Other adverse effects, such as interference with antihypertensive agents potential produce renal dysfunction patients compromised function inhibitors, seem similar those